Haemonetics
170 hedge funds and large institutions have $1.86B invested in Haemonetics in 2014 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 55 increasing their positions, 75 reducing their positions, and 19 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less capital invested
Capital invested by funds: $1.95B → $1.86B (-$86.6M)
3% less funds holding
Funds holding: 175 → 170 (-5)
3.54% less ownership
Funds ownership: 107.15% → 103.61% (-3.5%)
16% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 19
27% less repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 75
Top Buyers
Top Sellers
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$35.3M |
| 2 |
Nordea Investment Management
Stockholm,
Sweden
|
-$15.1M |
| 3 |
Neuberger Berman Group
New York
|
-$13.1M |
| 4 |
PIM
Perkins Investment Management
Chicago,
Illinois
|
-$10.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$9.42M |
HAE Hedge Fund Activity: Q3 2014 in Review
170 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2014, worth a combined $1.86B — down 4.5% from $1.95B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of HAE and 16 opened new positions — a net loss of 3 holders — while 75 trimmed existing stakes and 55 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $35.6M. The largest seller was Camber Capital Management, exiting entirely with an estimated $35.3M sold.
- 170 institutional investors held Haemonetics (HAE) as of Q3 2014, down from 175 in Q2 2014.
- Funds reported $1.86B of Haemonetics stock for Q3 2014, down 4.5% quarter-over-quarter.
- 16 funds opened new Haemonetics positions in Q3 2014 and 19 closed out, a net change of -3 holders.
- The largest Haemonetics buyer in Q3 2014 was T. Rowe Price Associates, an estimated $35.6M added.
- The largest Haemonetics seller in Q3 2014 was Camber Capital Management, an estimated $35.3M sold.
Based on aggregated 13F filings for Q3 2014.